SGS, the world's leading testing, inspection and certification company, is pleased to announce that it has acquired CMIC, INC., a specialized provider of...
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are n...
MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced that it has secured the FDA's agreement to conduct a si...
Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, introd...
Zymo Research, a global leader in genomics tools, announced the launch of Zymo Services, a dedicated portfolio of end-to-end next-generation sequencing (...
First Foundation Labs (1FL), a life sciences AI company pioneering clinical and translational reasoning spun out of Luma Group, announced a collaboration...
Integrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis ...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to havelittle to no cancer remaining in the prostate after s...
As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade eviden...
As precision medicine continues to reshape cancer care, ensuring equitable access to genomic testing remains a critical priority. New research presented at...
WFI manufacturing and other capabilities support for pharmaceutical innovation, GLP‑1 therapies, and medical devices. ILC Dover, an Ingersoll Rand bus...
Ginkgo Bioworks announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-de...
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson&rsqu...
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weig...
© 2026 Biopharma Boardroom. All Rights Reserved.
